Cover Image
e-ISSN: 2717-7904

Ethical Principles and Publication Policy

Research and Publication Ethics

JPharmTech is committed to the highest standards of research and publication integrity and follows the Core Practices of the Committee on Publication Ethics (COPE), the ICMJE Recommendations and the Principles of Transparency and Best Practice in Scholarly Publishing (COPE, DOAJ, OASPA, WAME). Suspected misconduct is handled according to COPE flowcharts.

Plagiarism and similarity check
All submissions are screened with similarity-detection software before peer review. Manuscripts with an overall similarity index above 20% (excluding references), or above 5% from a single source, are evaluated by the editor and may be returned to the authors or rejected. Similarity scores are assessed together with the nature of the overlap. Plagiarism, duplicate or redundant publication, data fabrication or falsification, and image manipulation are considered serious misconduct.

Authorship
Authorship must meet the four ICMJE criteria. All authors must approve the final version and agree to be accountable for the work. The contribution of each author must be stated in the Author Contributions section. Any change in authorship after submission (addition, removal or reordering) requires a written request explaining the reason, signed by all authors, and the approval of the editor.

Ethics committee approval and permissions
Studies involving human participants, human material or data, clinical research, animal experiments or retrospective use of personal data require ethics committee approval. The name of the ethics committee, the date of approval and the decision number must be stated in the Materials and Methods section and in the Ethics Committee Approval section of the article. If approval is not required, this must be explicitly stated (“Ethics committee approval is not required for this study.”). Manuscripts that require but lack ethics committee approval will be rejected.

  • Human studies must comply with the Declaration of Helsinki, and written informed consent must be obtained and stated.
  • Animal studies must comply with national legislation on the welfare and protection of laboratory animals and with Directive 2010/63/EU or the Guide for the Care and Use of Laboratory Animals, and should be reported according to the ARRIVE 2.0 guidelines.
  • Permission must be obtained and stated for the use of scales, questionnaires, figures or images owned by others.
  • Studies on plants must comply with relevant institutional, national and international guidelines and legislation.

Conflicts of interest and funding
All authors must disclose any financial or non-financial interests that could be perceived as influencing the work, and all sources of funding with grant numbers. Editors and reviewers must declare conflicts of interest and recuse themselves from manuscripts where a conflict exists. Manuscripts submitted by editors or editorial board members are handled independently by another editor, and the submitting editor has no access to the review process.

Use of artificial intelligence (AI) tools
AI tools do not meet authorship criteria and cannot be listed as authors. Authors must disclose the use of AI-assisted tools (other than basic language and grammar checking) in the Methods or Acknowledgments section, specifying the tool and its purpose. Authors are fully responsible for the accuracy and integrity of the content. AI-generated images are not accepted unless they are part of the research design and clearly described. Reviewers and editors must not upload manuscripts or any part of them into AI tools, to protect confidentiality.

Data availability
Authors are encouraged to make the data supporting their findings available and to include a Data Availability Statement. Editors may request raw data during the review process.

Peer review
All research and review articles undergo double-blind peer review by at least two independent reviewers. Reviewers must keep manuscripts confidential and must not use any information from them for their own purposes.

Corrections, retractions and expressions of concern
Errors identified after publication are corrected through a published correction (erratum). Articles found to contain unreliable results or misconduct are retracted following COPE retraction guidelines. Retracted articles remain online, clearly marked as retracted, with a linked retraction notice. The editor may publish an expression of concern while an investigation is ongoing.

Appeals and complaints
Authors may appeal an editorial decision by sending a reasoned request to the editor-in-chief within 30 days. Appeals are evaluated by an editor not involved in the original decision, and the outcome is final. Complaints about the journal’s processes or about suspected misconduct can be sent to the editorial office and will be handled according to COPE guidance.


Open Access and Copyright Policy

JPharmTech is a fully open access journal. All articles are freely available on the internet immediately upon publication, without embargo, subscription or registration. Users may read, download, copy, distribute, print, search, link to the full texts, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose without prior permission from the publisher or the author, in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

Articles are published under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Authors retain the copyright of their work without restrictions and grant JPharmTech the right of first publication and a non-exclusive license to publish the article. Anyone may reuse, distribute and adapt the article, provided the original work is properly cited. The license is displayed on every published article.

JPharmTech charges no submission, processing or publication fees, and no fees for readers.

Self-archiving: Authors may deposit all versions of their work (submitted, accepted and published) in institutional or subject repositories without embargo, with a link to the published article.

Archiving: Published content is permanently archived through the DergiPark platform.

Last Update Time: 14 October 2026

17117  18771